Animalcare on track to launch new veterinary drug

Animalcare Group plc (AIM: ANCR), the international animal health business with Alychlo as a reference shareholder, has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) recommending a marketing authorisation for Daxocox (enflicoxib) in Europe.

Daxocox, a product that has the potential to play a leading role in the Animalcare growth story, is a novel COX 2 inhibitor for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs. Following the CVMP’s positive opinion, a marketing authorisation decision from the European Commission is anticipated early in the second quarter of 2021.

For more information: